Literature DB >> 17945033

The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer.

Erin Grothey, Edward Chu.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17945033     DOI: 10.1016/S1533-0028(11)70301-2

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


× No keyword cloud information.
  2 in total

1.  Evaluation of efficacy and safety of generic levofolinate in patients who received colorectal cancer chemotherapy.

Authors:  Hironori Fujii; Hirotoshi Iihara; Koji Yasuda; Katsuhiko Matsuura; Takao Takahashi; Kazuhiro Yoshida; Yoshinori Itoh
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

2.  Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer.

Authors:  Yong Sang Hong; Hyeon Jin Cho; Sun Young Kim; Kyung Hae Jung; Ji Won Park; Hyo Seong Choi; Jae Hwan Oh; Byung Chang Kim; Dae Kyung Sohn; Dae Yong Kim; Hee Jin Chang
Journal:  BMC Cancer       Date:  2009-07-21       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.